Theseus Pharmaceuticals Inc at Stifel Targeted Oncology Days (Virtual) Transcript

Apr 26, 2023 / 04:00PM GMT
Brad Canino - Stifel Financial Corp. - Analyst

Thanks, everyone, for continuing to join us on our inaugural Stifel Target Oncology Days. How many have as Brad Canino, senior analyst here at Stifel, and I'm delighted to be joined by Tim Clackson, the CEO of Theseus, to sit down with me for a about 25-minute fireside chat. So thank you so much, Tim, for joining us.

Tim Clackson - Theseus Pharmaceuticals, Inc. - President & CEO

Thanks, Brad, for the opportunity.

Questions and Answers:

Brad Canino - Stifel Financial Corp. - Analyst

Cool. Now I think we'll open with a company question but somewhat of a specific question, because I'd love you to just talk about your PRA tool that you use, define it; and why it's important for mutant protein targets, particularly for the drugs in targeted cancers in your pipeline?

Tim Clackson - Theseus Pharmaceuticals, Inc. - President & CEO

Of course. Happy to do that. So PRA stand so the Predictive Resistance Assay. Why are we
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot